1
|
Tedbirt B, Maho-Vaillant M, Houivet E, Mignard C, Golinski ML, Calbo S, Prost-Squarcioni C, Labeille B, Picard-Dahan C, Chaby G, Richard MA, Tancrede-Bohin E, Duvert-Lehembre S, Delaporte E, Bernard P, Caux F, Alexandre M, Musette P, Ingen-Housz-Oro S, Vabres P, Quereux G, Dupuy A, Debarbieux S, Avenel-Audran M, D’Incan M, Bédane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Benichou J, Joly P, Hébert V. Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 Trial. JAMA Dermatol 2024; 160:290-296. [PMID: 38265821 PMCID: PMC10809134 DOI: 10.1001/jamadermatol.2023.5679] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Accepted: 11/03/2023] [Indexed: 01/25/2024]
Abstract
Importance The Ritux 3 trial demonstrated the short-term efficacy and safety of first-line treatment with rituximab compared with a standard corticosteroid regimen in pemphigus. No data on the long-term follow-up of patients who received rituximab as first line are available. Objective To assess the long-term efficacy and safety of the Ritux 3 treatment regimen. Design, Setting, and Participants This 7-year follow-up study of the Ritux 3 trial included patients with pemphigus from 25 dermatology departments in France from January 1, 2010, to December 31, 2015. Exposure Patients were initially randomized in the rituximab plus prednisone group or prednisone-alone group. Main outcomes and measures The primary outcome was the 5- and 7-year disease-free survival (DFS) without corticosteroids, assessed by Kaplan-Meier curves. Secondary outcomes were occurrence of relapse, occurrence of severe adverse events (SAEs), and evolution of antidesmoglein (Dsg) antibody enzyme-linked immunosorbent assay values to predict long-term relapse. Results Of the 90 patients in the Ritux 3 trial, 83 were evaluated at the end of follow-up study visit (44 in the rituximab plus prednisone group; 39 in the prednisone-alone group) with a median (IQR) follow-up of 87.3 (79.1-97.5) months. Forty-three patients (93%) from the rituximab plus prednisone and 17 patients (39%) from the prednisone-alone group had achieved complete remission without corticosteroids at any time during the follow-up. Patients from the rituximab group had much longer 5- and 7-year DFS without corticosteroids than patients from the prednisone-alone group (76.7% and 72.1% vs 35.3% and 35.3%, respectively; P < .001), and had about half the relapses (42.2% vs 83.7%; P < .001). Patients who received rituximab as second-line treatment had shorter DFS than patients treated as first line (P = .007). Fewer SAEs were reported in the rituximab plus prednisone group compared with the prednisone-alone group, 31 vs 58 respectively, corresponding to 0.67 and 1.32 SAEs per patient, respectively (P = .003). The combination of anti-Dsg1 values of 20 or more IU/mL and/or anti-Dsg3 values of 48 or more IU/mL yielded 0.83 positive predictive value and 0.94 negative predictive value to predict long-term relapse. Conclusions and Relevance In this secondary analysis of the Ritux 3 trail, first-line treatment of patients with pemphigus with the Ritux 3 regimen was associated with long-term sustained complete remission without corticosteroid therapy without any additional maintenance infusion of rituximab.
Collapse
Affiliation(s)
- Billal Tedbirt
- Department of Dermatology, CHU Rouen and INSERM U1234, Normandie University, Rouen, France
| | - Maud Maho-Vaillant
- Department of Dermatology, CHU Rouen and INSERM U1234, Normandie University, Rouen, France
| | - Estelle Houivet
- Department of Biostatistics and Clinical Research, CHU Rouen, Rouen, France
| | - Claire Mignard
- Department of Dermatology, CHU Rouen and INSERM U1234, Normandie University, Rouen, France
| | - Marie-Laure Golinski
- Department of Dermatology, CHU Rouen and INSERM U1234, Normandie University, Rouen, France
| | - Sébastien Calbo
- Department of Dermatology, CHU Rouen and INSERM U1234, Normandie University, Rouen, France
| | - Catherine Prost-Squarcioni
- Department of Dermatology, Centre de référence des maladies bulleuses auto-immunes, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris 13, Bobigny, France
| | - Bruno Labeille
- Department of Dermatology, University of Saint-Étienne, Saint-Étienne, France
| | | | - Guillaume Chaby
- Department of Dermatology, University of Amiens, Amiens, France
| | - Marie-Aleth Richard
- CEReSS-EA 3279, Research Centre in Health Services and Quality of Life Aix Marseille University, Dermatology Department, Universitaire Hospital Timone, Assistance Publique Hôpitaux de Marseille, APHM, 13385, Marseille, France
| | | | | | | | | | - Frédéric Caux
- Department of Dermatology, Centre de référence des maladies bulleuses auto-immunes, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris 13, Bobigny, France
| | - Marina Alexandre
- Department of Dermatology, Centre de référence des maladies bulleuses auto-immunes, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris 13, Bobigny, France
| | - Philippe Musette
- Department of Dermatology, Centre de référence des maladies bulleuses auto-immunes, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris 13, Bobigny, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Henri Mondor Hospital, Univ Paris Est Créteil EpiDermE, Créteil, France
| | - Pierre Vabres
- Department of Dermatology, Dijon University Hospital, Dijon, France
| | - Gaëlle Quereux
- Department of Dermatology, University of Nantes, Nantes, France
| | - Alain Dupuy
- Department of Dermatology, University of Rennes, Rennes, France
| | - Sébastien Debarbieux
- Department of Dermatology, Centre Hospitalier Lyon Sud, Pierre Bénite, Lyon, France
| | | | - Michel D’Incan
- Department of Dermatology, University of Clermont-Ferrand, Clermont-Ferrand, France
| | | | - Nathalie Bénéton
- Department of Dermatology, Le Mans General Hospital, Le Mans, France
| | - Denis Jullien
- Department of Dermatology, Edouard Herriot Hospital, Lyon Claude Bernard University, Lyon, France
| | - Nicolas Dupin
- Department of Dermatology, APHP and University of Paris cité, Paris, France
| | - Laurent Misery
- Department of Dermatology, Brest University Hospital, Brest, France
| | - Laurent Machet
- Department of Dermatology, Tours University Hospital, Tours, France
| | | | - Olivier Dereure
- Department of Dermatology, University of Montpellier, Montpellier, France
| | - Bruno Sassolas
- Department of Internal Medicine, Brest University Hospital, Brest, France
| | - Jacques Benichou
- Department of Biostatistics and Clinical Research, CHU Rouen and Inserm U1018, Université Paris-Saclay and Université de Rouen, Rouen, France
| | - Pascal Joly
- Department of Dermatology, CHU Rouen and INSERM U1234, Normandie University, Rouen, France
| | - Vivien Hébert
- Department of Dermatology, CHU Rouen and INSERM U1234, Normandie University, Rouen, France
| | | |
Collapse
|
2
|
Amini-Adle M, Arnault JP, Aubin F, Beneton N, Bens G, Brunet-Possenti F, Célerier P, Charles J, Crumbach L, Dalac S, Darras S, De Quatrebarbes J, Dinulescu M, Dutriaux C, Gaudy C, Gérard E, Giacchero D, Granel-Brocard F, Grange F, Jouary T, Kramkimel N, Lebbé C, Le Corre Y, Legoupil D, Lesage C, Lesimple T, Lorphelin JM, Mansard S, Martin L, Mary-Prey S, Maubec E, Meyer N, Mignard C, Montaudie H, Mortier L, Nardin C, Neidhardt Berard EM, Pagès Laurent C, Peuvrel L, Quereux G, Robert C, Saiag P, Saint-Jean M, Samimi M, Sassolas B, Scalbert C, Skowron F, Steff M, Stoebner PE, Trablesi S, Visseaux L, Zehou O, Boespflug A. The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns. Ann Dermatol Venereol 2024; 151:103243. [PMID: 38325268 DOI: 10.1016/j.annder.2023.103243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2023] [Revised: 04/06/2023] [Accepted: 09/05/2023] [Indexed: 02/09/2024]
Affiliation(s)
- M Amini-Adle
- Dermatology Department, Centre Léon Bérard, Lyon, France.
| | - J-P Arnault
- Dermatology Department, Centre Hospitalo-Universitaire, Amiens Picardie, France
| | - F Aubin
- Université de Bourgogne-Franche-Comté, Dermatology Department, Head of the Skin Cancer Unit, Centre Hospitalo-Universitaire de Besançon, Besançon, France; INSERM UMR RIGHT 1098, Besançon, France
| | - N Beneton
- Dermatology Department, Centre Hospitalier, Le Mans, France
| | - G Bens
- Dermatology Department, Centre Hospitalier, Orléans, France
| | - F Brunet-Possenti
- Dermatology Department, Centre Hospitalo-Universitaire Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - P Célerier
- Dermatology Department, Centre Hospitalier La Rochelle-Ré-Aunis, La Rochelle, France
| | - J Charles
- Dermatology Department, Centre Hospitalo-Universitaire, Grenoble, France
| | - L Crumbach
- Dermatology Department, Centre Léon Bérard, Lyon, France
| | - S Dalac
- Dermatology Department, Centre Hospitalo-Universitaire, Dijon, France
| | - S Darras
- Dermatology Department, Centre Hospitalier de Boulogne-sur-Mer, France
| | - J De Quatrebarbes
- Dermatology Department, Centre Hospitalier Annecy Genevois, Annecy, France
| | - M Dinulescu
- Dermatology Department, Centre Hospitalo-Universitaire, Rennes, France
| | - C Dutriaux
- Dermatology Department, Centre Hospitalo-Universitaire, Bordeaux, France
| | - C Gaudy
- Dermatology Department, Centre Hospitalo-Universitaire, Marseille, France
| | - E Gérard
- Dermatology Department, Centre Hospitalo-Universitaire, Bordeaux, France
| | | | - F Granel-Brocard
- Dermatology Department, Hôpitaux de Brabois Allée de Morvan, Vandoeuvre Les Nancy, France
| | - F Grange
- Dermatology Department, Centre Hospitalier, Valence, France
| | - T Jouary
- Dermatology Department, Hôpital François Mitterrand, Pau, France
| | - N Kramkimel
- Dermatology Department, Centre Hospitalo-Universitaire Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - C Lebbé
- Dermatology Department, Centre Hospitalo-Universitaire Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Y Le Corre
- Dermatology Department, Centre Hospitalo-Universitaire Angers, France
| | - D Legoupil
- Dermatology Department, Centre Hospitalo-Universitaire Régional, Brest, France
| | - C Lesage
- Dermatology Department, Hôpital Saint Eloi, Montpellier, France
| | | | - J-M Lorphelin
- Dermatology Department, Centre Hospitalo-Universitaire, Caen, France
| | - S Mansard
- Dermatology Department, Centre Hospitalo-Universitaire, Clermont Ferrand, France
| | - L Martin
- Dermatology Department, Centre Hospitalo-Universitaire, Angers, France; Groupe Ethique de la Société Française de Dermatologie, France
| | - S Mary-Prey
- Centre Hospitalo-Universitaire Saint André, Bordeaux, France
| | - E Maubec
- Dermatology Department, Centre Hospitalo-Universitaire Avicenne, Assistance Publique-Hôpitaux de Paris, Bobigny, France
| | - N Meyer
- Institut Universitaire du Cancer et Centre Hospitalo-Universitaire, Toulouse, France
| | - C Mignard
- Dermatology Department, Centre Hospitalo-Universitaire, Rouen, France
| | - H Montaudie
- Dermatology Department, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France; INSERM U1065, Team 12, Centre Méditerranéen de Médecine Moléculaire, Université Nice Côte d'Azur, Nice, France
| | - L Mortier
- Dermatology Department, Centre Hospitalier Régional Universitaire, Lille, France
| | - C Nardin
- Université de Bourgogne-Franche-Comté et Centre Hospitalier Universitaire, Besançon, France; IINSERM UMR RIGHT 1098, Besançon, France
| | | | - C Pagès Laurent
- Institut Universitaire du Cancer et Centre Hospitalo-Universitaire, Toulouse, France
| | - L Peuvrel
- Medical Oncology Department, Institut de Cancérologie de l'Ouest, Saint Herblain, France
| | - Gaelle Quereux
- Dermatology Department, Centre Hospitalo-Universitaire, Nantes Université, Nantes, France; INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302, Nantes, France
| | - Caroline Robert
- Dermatology Department, Institut Gustave Roussy, Villejuif, France
| | - Philippe Saiag
- Dermatology Department, Centre Hospitalo-Universitaire Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Boulogne Billancourt, France
| | - Mélanie Saint-Jean
- Medical Oncology Department, Institut de Cancérologie de l'Ouest, Saint Herblain, France
| | - M Samimi
- Dermatology Department, Centre Hospitalo-Universitaire, Tours, France
| | - B Sassolas
- Institute of Oncology & Hematology, Hôpital Morvan, Centre Hospitalier Régional Universitaire, Brest, France
| | - C Scalbert
- Dermatology Department, Centre Hospitalier Ouest Réunion, Saint Paul, Ile de la Réunion, France
| | - F Skowron
- Dermatology Department, Hôpitaux Drome Nord, Romans Sur Isère, France
| | - M Steff
- Dermatology Department, Centre Hospitalier Intercommunal Robert Ballanger, Aulnay sous-Bois, France
| | - P-E Stoebner
- Dermatology Department, Centre Hospitalo-Universitaire, Nîmes, France
| | - S Trablesi
- Dermatology Department, Centre Hospitalo-Universitaire, Grenoble, France
| | - L Visseaux
- Polyclinique Reims Bezannes, Bezannes, France
| | - O Zehou
- Dermatology Department, Centre Hospitalo-Universitaire Henri Mondor, Assistance Publique-Hôpitaux de Paris, Créteil, France
| | - A Boespflug
- Dermatology Department, Centre Hospitalier Henri Mondor, Villejuif, France
| |
Collapse
|
3
|
Lafon A, Mignard C, Castel M, Duval-Modeste AB, Joly P. COVID-19 : adhésion à la vaccination chez des patients immunodéprimés de dermatologie. Annales de Dermatologie et de Vénéréologie - FMC 2021. [PMCID: PMC8603661 DOI: 10.1016/j.fander.2021.09.393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
Introduction La pandémie COVID-19 a été responsable d’une mortalité importante, d’autant plus chez les patients immunodéprimés. La vaccination contre le COVID a suscité des doutes chez les patients, la récente technique de vaccination par ARN messager étant méconnue du grand public. Nous avons observé la prévalence de la vaccination chez des patients immunodéprimés suivis en hôpital de jour de dermatologie et les éventuels freins à cette vaccination chez les patients ayant refusé. Matériel et méthodes Nous avons inclus l’ensemble des patients suivis en HDJ depuis le mois de mai 2020 pour une pathologie traitée par immunosuppresseur rentrant dans les critères de vaccination au 15 mai 2021. Nous avons recueilli rétrospectivement la date de vaccination, le type de vaccin, l’éventuelle raison du refus de vaccination et l’antécédent d’infection par le COVID-19. Résultats Nous avons inclus 65 patients suivis en HDJ au CHU de Rouen (37 F et 28 H) âgés de 23 à 90 ans (moyenne 68,3 ans). Cinquante et un sur 65 (78,4 %) étaient atteints de maladie bulleuse et 11/65 (16,9 %) d’un cancer cutané. Quarante (61,5 %) patients étaient traités par rituximab. Deux patients ont été perdus de vue. Cinquante-trois (81,5 %) patients ont été vaccinés par vaccin à ARN messager. Les 10 patients non vaccinés étaient traités pour une maladie bulleuse par rituximab ou mycophénolate mofétil. La raison était : manque de confiance dans le vaccin (5/10), perfusion de rituximab trop proche (2/10), examens ou chirurgie programmés (2/10) et infection au COVID récente (1/10). Vingt-huit patients ont été vaccinés dans le service. Seulement 2/65 patients ont déclaré été testés positifs au COVID-19 avant le vaccin, 1 seul a été infecté après la 1re dose. Les ⅔ des patients avaient accompli l’ensemble de leur vaccination à la fin du mois d’avril 2021. Discussion Notre étude montre : – 80 % de vaccinés dans une population à risque témoignant d’une sensibilisation accrue des patients malgré un climat de scepticisme ; du bénéfice de l’organisation d’une campagne vaccinale dans le service permettant un meilleur accès aux vaccins notamment chez les plus âgés ; – 3/65 infections symptomatiques : chiffre en dessous de l’incidence de la population générale montrant une importante vigilance des immunodéprimés sensibilisés aux gestes barrières. La plupart des patients nous ont confié s’être isolés de leurs proches pour se protéger ; – les patients ayant refusé la vaccination étant les plus jeunes de la cohorte (54 ans en moyenne). La vague de défiance contre la vaccination trouve plutôt un public chez des jeunes ayant facilement accès à internet et aux « fake news » remettant en question le principe de la vaccination, la protection individuelle et collective. En conclusion, la vaccination reste un moyen sûr de protéger les patients sous immunosuppresseur à la condition d’avoir un discours clair et rassurant quitte à leur proposer un environnement plus facile d’accès pour la réaliser.
Collapse
|
4
|
Mignard C, Maho-Vaillant M, Golinski ML, Balayé P, Prost-Squarcioni C, Houivet E, Calbo SB, Labeille B, Picard-Dahan C, Konstantinou MP, Chaby G, Richard MA, Bouaziz JD, Duvert-Lehembre S, Delaporte E, Bernard P, Caux F, Alexandre M, Ingen-Housz-Oro S, Vabres P, Quereux G, Dupuy A, Debarbieux S, Avenel-Audran M, D'Incan M, Bédane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Benichou J, Joly P, Hébert V. Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy: A Post Hoc Analysis of a Randomized Clinical Trial. JAMA Dermatol 2020; 156:545-552. [PMID: 32186656 DOI: 10.1001/jamadermatol.2020.0290] [Citation(s) in RCA: 34] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Importance Rituximab and short-term corticosteroid therapy are the criterion standard treatments for patients with newly diagnosed moderate to severe pemphigus. Objective To examine factors associated with short-term relapse in patients with pemphigus treated with rituximab. Design, Setting, and Participants This post hoc analysis of a randomized clinical trial (Comparison Between Rituximab Treatment and Oral Corticosteroid Treatment in Patients With Pemphigus [RITUX 3]) conducted from January 1, 2010, to December 31, 2015, included patients from 20 dermatology departments of tertiary care centers in France from the RITUX 3 trial and 3 newly diagnosed patients treated according to the trial protocol. Data analysis was performed from February 1 to June 30, 2019. Exposure Patients randomly assigned to the rituximab group in the RITUX 3 trial and the 3 additional patients were treated with 1000 mg of intravenous rituximab on days 0 and 14 and 500 mg at months 12 and 18 combined with a short-term prednisone regimen. Main Outcomes and Measures Baseline (pretreatment) clinical and biological characteristics (Pemphigus Disease Area Index [PDAI] score, ranging from 0-250 points, with higher values indicating more severe disease) and changes in anti-desmoglein (DSG) 1 and anti-DSG3 values as measured by enzyme-linked immunosorbent assay during the 3 months after rituximab treatment were compared between patients with disease relapse and those who maintained clinical remission during the first 12 months after treatment. The positive and negative predictive values of these factors were calculated. Results Among 47 patients (mean [SD] age, 54.3 [17.0] years; 17 [36%] male and 30 [64%] female) included in the study, the mean (SD) baseline PDAI score for patients with relapsing disease was higher than that of the patients with nonrelapsing disease (54 [33] vs 28 [24]; P = .03). At month 3, 7 of 11 patients with relapsing disease (64%) vs 7 of 36 patients with nonrelapsing disease (19%) had persistent anti-DSG1 antibody values of 20 IU/mL or higher and/or anti-DSG3 antibody values of 130 IU/mL or higher (P = .01). A PDAI score of 45 or higher defining severe pemphigus and/or persistent anti-DSG1 antibody values of 20 IU/mL or higher and/or anti-DSG3 antibody values of 130 IU/mL or higher at month 3 provided a positive predictive value of 50% (95% CI, 27%-73%) and a negative predictive value of 94% (95% CI, 73%-100%) for the occurrence of relapse after rituximab. Conclusions and Relevance The findings suggest that initial PDAI score and changes in anti-DSG antibody values after the initial cycle of rituximab might help differentiate a subgroup of patients with high risk of relapse who might benefit from maintenance rituximab infusion at month 6 from a subgroup of patients with low risk of relapse who do not need early maintenance therapy. Trial Registration NCT00784589.
Collapse
Affiliation(s)
- Claire Mignard
- Centre de référence des maladies bulleuses auto-immunes, Department of Dermatology, Rouen University Hospital, Normandie University, INSERM U1234, Rouen, France
| | - Maud Maho-Vaillant
- Centre de référence des maladies bulleuses auto-immunes, Department of Dermatology, Rouen University Hospital, Normandie University, INSERM U1234, Rouen, France
| | - Marie-Laure Golinski
- Centre de référence des maladies bulleuses auto-immunes, Department of Dermatology, Rouen University Hospital, Normandie University, INSERM U1234, Rouen, France
| | - Pierre Balayé
- Department of Biostatistics and Clinical Research, Rouen University Hospital, Rouen, France
| | - Catherine Prost-Squarcioni
- Centre de référence des maladies bulleuses auto-immunes, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris, Department of Dermatology, University of Paris 13, Bobigny, France
| | - Estelle Houivet
- Department of Biostatistics and Clinical Research, Rouen University Hospital, Rouen, France
| | - Sé Bastien Calbo
- Centre de référence des maladies bulleuses auto-immunes, Department of Dermatology, Rouen University Hospital, Normandie University, INSERM U1234, Rouen, France
| | - Bruno Labeille
- Department of Dermatology, University of Saint Etienne, Saint Etienne, France
| | | | | | - Guillaume Chaby
- Department of Dermatology, University of Amiens, Amiens, France
| | - Marie-Aleth Richard
- Assistance Publique des Hôpitaux de Marseille, Department of Dermatology, Aix Marseille University, UMR 911, INSERM CRO2, Marseille, France
| | - Jean-David Bouaziz
- Department of Dermatology, St Louis Hospital, Paris 7 Sorbonne Paris Cité University, Paris, France
| | | | | | | | - Frédéric Caux
- Centre de référence des maladies bulleuses auto-immunes, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris, Department of Dermatology, University of Paris 13, Bobigny, France
| | - Marina Alexandre
- Centre de référence des maladies bulleuses auto-immunes, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris, Department of Dermatology, University of Paris 13, Bobigny, France
| | - Saskia Ingen-Housz-Oro
- Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France
| | - Pierre Vabres
- Department of Dermatology, Dijon University Hospital, Dijon, France
| | - Gaëlle Quereux
- Department of Dermatology, University of Nantes, Nantes, France
| | - Alain Dupuy
- Department of Dermatology, University of Rennes, Rennes, France
| | - Sébastien Debarbieux
- Department of Dermatology, Centre Hospitalier Lyon Sud, Pierre Bénite, Lyon, France
| | | | - Michel D'Incan
- Department of Dermatology, University of Clermont-Ferrand, Clermont-Ferrand, France
| | | | - Nathalie Bénéton
- Department of Dermatology, Le Mans General Hospital, Le Mans, France
| | - Denis Jullien
- Department of Dermatology, Edouard Herriot Hospital, Lyon Claude Bernard University, Lyon, France
| | - Nicolas Dupin
- Department of Dermatology, University of Paris V, Paris, France
| | - Laurent Misery
- Department of Dermatology, Brest University Hospital, Brest, France
| | - Laurent Machet
- Department of Dermatology, Tours University Hospital, Tours, France
| | | | - Olivier Dereure
- Department of Dermatology, University of Montpellier, Montpellier, France
| | - Bruno Sassolas
- Department of Internal Medicine, Brest University Hospital, Brest, France
| | - Jacques Benichou
- Department of Biostatistics and Clinical Research, Rouen University Hospital, Rouen, France
| | - Pascal Joly
- Centre de référence des maladies bulleuses auto-immunes, Department of Dermatology, Rouen University Hospital, Normandie University, INSERM U1234, Rouen, France
| | - Vivien Hébert
- Centre de référence des maladies bulleuses auto-immunes, Department of Dermatology, Rouen University Hospital, Normandie University, INSERM U1234, Rouen, France
| | | |
Collapse
|
5
|
Lemieux A, Maho-Vaillant M, Golinski ML, Hébert V, Mignard C, Calbo S, Candon S, Joly P. Influence des anticorps anti-rituximab dans le traitement des patients atteints de pemphigus. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
6
|
Hébert V, Vermeulin T, Tanguy L, Tedbirt B, Mignard C, Bénichou J, Joly P. Comparison of real costs in the French healthcare system in newly diagnosed patients with pemphigus for first‐line treatment with rituximab vs. standard corticosteroid regimen: data from a national multicentre trial. Br J Dermatol 2020; 183:121-127. [DOI: 10.1111/bjd.18563] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/24/2019] [Indexed: 12/11/2022]
Affiliation(s)
- V. Hébert
- Department of Dermatology Rouen University Hospital, and INSERM U 1234 Centre de Référence des Maladies Bulleuses Auto‐immunes Normandie University Rouen France
| | - T. Vermeulin
- Department of Biostatistics and Clinical Research INSERM U 1219 Rouen University Hospital University of Rouen Rouen France
| | - L. Tanguy
- Department of Biostatistics and Clinical Research INSERM U 1219 Rouen University Hospital University of Rouen Rouen France
| | - B. Tedbirt
- Department of Dermatology Rouen University Hospital, and INSERM U 1234 Centre de Référence des Maladies Bulleuses Auto‐immunes Normandie University Rouen France
| | - C. Mignard
- Department of Dermatology Rouen University Hospital, and INSERM U 1234 Centre de Référence des Maladies Bulleuses Auto‐immunes Normandie University Rouen France
| | - J. Bénichou
- Department of Biostatistics and Clinical Research INSERM U 1219 Rouen University Hospital University of Rouen Rouen France
| | - P. Joly
- Department of Dermatology Rouen University Hospital, and INSERM U 1234 Centre de Référence des Maladies Bulleuses Auto‐immunes Normandie University Rouen France
| |
Collapse
|
7
|
Mignard C, Maho-Vaillant M, Prost-Squarcioni C, Calbo S, Golinski ML, Labeille B, Picard-Dahan C, Konstantinou M, Richard MA, Bouaziz J, Duvert-Lehembre S, Bernard P, Caux F, Alexandre M, Oro S, Vabres P, Quereux G, Dupuy A, Debarbieux S, Martin L, D’Incan M, Bedane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Hébert V, Joly P. Facteurs pronostiques de rechute à long terme chez les patients atteints de pemphigus traités par rituximab en première ligne. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
8
|
Mignard C, Barrel A, Carvalho P, Joly P. Nicotinamide pour la prévention des carcinomes cutanés. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
9
|
Mignard C, Hébert V, Maho-Vaillant M, Calbo S, Bénichou J, Joly P. Facteurs de risque de rechute précoce chez les patients atteints de pemphigus traités par rituximab en première ligne. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
10
|
Mignard C, Deschamps-Huvier A, Duval-Modeste AB, Dutriaux C, Khammari A, Avril MF, Mortier L, Lesimple T, Gaudy-Marqueste C, Lesage C, Machet L, Aubin F, Meyer N, Beneton Benhard N, Jeudy G, Montaudié H, Arnault JP, Leccia MT, Joly P, Oncology Research Group Of The French Society Of Dermatology S. Efficacy of immunotherapy in patients with metastatic mucosal or uveal melanoma. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy289.026] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Castel M, Mignard C, Andrieu E, Duval Modeste AB, Joly P. Réactivation EBV compliquée d’un syndrome d’activation macrophagique chez 3 patients traités pour un mélanome métastatique. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
12
|
Mignard C, Duval Modeste AB, Guignant M, Samain A, Joly P. Évaluation de la tolérance du cobimétinib en vie réelle. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.608] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
13
|
Mignard C, Pinard C, Andrieu E, Duval Modeste A, Joly P. Brentuximab vedotin : traitement du mycosis fongoïde CD30 négatif. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.549] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
14
|
Deschamps A, Mignard C, Samain A, Modeste ABD, Joly P. Évaluation de la réponse des mélanomes muqueux et choroïdiens à l’immunothérapie par anti-CTLA4 et/ou anti-PD1. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.239] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
15
|
Mignard C, Litrowski N, Carré D, Midhat M, Dupin N, Bravard P. [Syphilitic osteitis in an HIV-negative patient]. Ann Dermatol Venereol 2016; 143:682-686. [PMID: 27020963 DOI: 10.1016/j.annder.2016.02.019] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2015] [Revised: 12/18/2015] [Accepted: 02/12/2016] [Indexed: 11/30/2022]
Abstract
BACKGROUND Secondary syphilis with skeletal involvement is rare; herein we report a case concerning an HIV-negative patient. PATIENTS AND METHODS During the course of secondary syphilis, a 28-year-old male homosexual, HIV-negative and with no medical history, presented intense and localized headaches persisting despite three weeks of antibiotic therapy. Bone scintigraphy revealed three bone lesions evocative of syphilitic osteitis, for which prolonged antibiotic therapy was instituted. DISCUSSION Few cases of syphilitic osteitis have been described in the recent literature and these are linked to haematogenous diffusion of Treponema pallidum. Skeletal disease is suggested when febrile bone pain is present. Bone scintigraphy remains the best diagnostic tool and treatment comprises prolonged penicillin G or ceftriaxone.
Collapse
Affiliation(s)
- C Mignard
- Service de dermatologie, hôpital J.-Monod, groupe hospitalier du Havre, BP 24, 76083 Le Havre, France.
| | - N Litrowski
- Service de dermatologie, hôpital J.-Monod, groupe hospitalier du Havre, BP 24, 76083 Le Havre, France
| | - D Carré
- Service de dermatologie, hôpital J.-Monod, groupe hospitalier du Havre, BP 24, 76083 Le Havre, France
| | - M Midhat
- Service de dermatologie, hôpital J.-Monod, groupe hospitalier du Havre, BP 24, 76083 Le Havre, France
| | - N Dupin
- CNR-Syphilis, laboratoire de dermatologie, hôpital Cochin, bâtiment Gustave-Roussy, 8, rue Méchain, 75014 Paris, France
| | - P Bravard
- Service de dermatologie, hôpital J.-Monod, groupe hospitalier du Havre, BP 24, 76083 Le Havre, France
| |
Collapse
|
16
|
Mignard C, Mirjolet J, Kissel H, Bichat F, Duchamp O. 54 Characterization of NOG Mice Reconstituted with Human Hematopoietic Stem Cells (HSC) or Mature Peripheral Blood Mononuclear Cells (PBMC). Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71852-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
17
|
Guettard E, Campech M, Mignard C, Masanovic M. Friedreich ataxia and bladder disorders. Ann Phys Rehabil Med 2012. [DOI: 10.1016/j.rehab.2012.07.961] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
18
|
Guettard E, Campech M, Mignard C, Masanovic M. Ataxie de Friedreich et troubles vésicosphinctériens, étude à partir d’une population réunionnaise. Ann Phys Rehabil Med 2012. [DOI: 10.1016/j.rehab.2012.07.954] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
19
|
Bintner M, Dumas H, Mignard C, Mignard D. 2-37-06 Cerebral venous thrombosis imaging in reunion island: 35 patients. J Neurol Sci 1997. [DOI: 10.1016/s0022-510x(97)85464-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
20
|
Fardeau M, Eymard B, Mignard C, Tomé FM, Richard I, Beckmann JS. Chromosome 15-linked limb-girdle muscular dystrophy: clinical phenotypes in Reunion Island and French metropolitan communities. Neuromuscul Disord 1996; 6:447-53. [PMID: 9027854 DOI: 10.1016/s0960-8966(96)00387-2] [Citation(s) in RCA: 61] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Erb's type limb-girdle muscular dystrophy (LGMD) was identified and clinically studied in detail in a small community living in the Reunion Island (RI). It was linked to chromosome 15q and related to mutations in the muscle specific calpain 3 gene. A series of cases were afterwards clinically and genetically identified in the French metropolitan community. The phenotype was identical to the RI type in the great majority of cases, although clinical differences were noticed in a few cases. Six different mutations were identified in the RI families, whereas a series of 39 mutations were detected in the French metropolitan families, all different from those present in the RI patients. Phenotype-genotype correlations were attempted in both communities.
Collapse
Affiliation(s)
- M Fardeau
- INSERM U153, Hôpital de la Salpêtrière, Paris, France
| | | | | | | | | | | |
Collapse
|
21
|
Abstract
BACKGROUND Friedreich's ataxia, the most common inherited ataxia, is associated with a mutation that consists of an unstable expansion of GAA repeats in the first intron of the frataxin gene on chromosome 9, which encodes a protein of unknown function. METHODS We studied 187 patients with autosomal recessive ataxia, determined the size of the GAA expansions, and analyzed the clinical manifestations in relation to the number of GAA repeats and the duration of disease. RESULTS One hundred forty of the 187 patients, with ages at onset ranging from 2 to 51 years, were homozygous for a GAA expansion that had 120 to 1700 repeats of the trinucleotides. About one quarter of the patients, despite being homozygous, had atypical Friedreich's ataxia; they were older at presentation and had intact tendon reflexes. Larger GAA expansions correlated with earlier age at onset and shorter times to loss of ambulation. The size of the GAA expansions (and particularly that of the smaller of each pair) was associated with the frequency of cardiomyopathy and loss of reflexes in the upper limbs. The GAA repeats were unstable during transmission. CONCLUSIONS The clinical spectrum of Friedreich's ataxia is broader than previously recognized, and the direct molecular test for the GAA expansion on chromosome 9 is useful for diagnosis, determination of prognosis, and genetic counseling.
Collapse
Affiliation(s)
- A Dürr
- Fédération de Neurologie and INSERM Unité 289, Hôpital de la Saltpétriere, Paris, France
| | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Fardeau M, Hillaire D, Mignard C, Feingold N, Feingold J, Mignard D, de Ubeda B, Collin H, Tome FM, Richard I, Beckmann J. Juvenile limb-girdle muscular dystrophy. Clinical, histopathological and genetic data from a small community living in the Reunion Island. Brain 1996; 119 ( Pt 1):295-308. [PMID: 8624690 DOI: 10.1093/brain/119.1.295] [Citation(s) in RCA: 128] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
A series of patients affected by a muscular dystrophy, similar to the original description of a juvenile scapulo-humeral form by Erb in 1884 and fitting with the criteria used to define limb-girdle muscular dystrophies, was discovered in a small community living in the southern part of Reunion Island in the Indian Ocean. A detailed clinical analysis was conducted over 5 years on a cohort of 20 patients. This community presented a high degree of consanguinity as it was segregated from the majority of the island population for more than a century. In previous molecular genetic studies, the disease locus has been mapped to chromosome 15p. Mutations were recently identified in a gene located in this region encoding for muscle-specific calcium activated neutral protease (CANP3). Clinical, pathological, genetic and complete identification of the mutations are presented here, establishing, for the first time, precise clinico-genetic correlations in this form of autosomal recessive, juvenile, limb-girdle muscular dystrophy (LGMD).
Collapse
|
23
|
Michault A, Rivière B, Fressy P, Laporte JP, Bertil G, Mignard C. [Contribution of enzyme-linked immuno-electrotransfer blot assay for the diagnosis of human neurocysticercosis]. Pathol Biol (Paris) 1990; 38:119-25. [PMID: 2314931] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
An enzyme-linked immunoelectrotransfer blot (EITB) is developed for immunodiagnosing human neurocysticercosis. The assay's efficacy is evaluated in 71 neurocysticercotic patients whose diagnosis of the disease and evaluation of disease activity is based on CT scan findings. We identified eight bands (molecular weigh less than 35 000) that evaluate the disease activity: active disease, calcification in progress, inactive disease. All samples patients with active disease recognized 14 000 band. This band is missing in the others parasitic diseases and in serum of the patients with inactive diseases or calcification in progress. The enzyme-linked immunoelectrotransfer blot is simple to perform and may be used in sero-epidemiology.
Collapse
Affiliation(s)
- A Michault
- Service de Bactériologie-Parasitologie, Centre Hospitalier Général Saint-Pierre
| | | | | | | | | | | |
Collapse
|
24
|
Michault A, Leroy D, Coubes P, Laporte JP, Bertil G, Mignard C. [Immunologic diagnosis of the cerebrospinal fluid and serum in developing brain cysticercosis]. Pathol Biol (Paris) 1989; 37:249-53. [PMID: 2660076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
ELISA detection of specific antibodies in the serum (IgG) and cerebrospinal fluid (IgG, IgM and IgA) was evaluated in 28 patients. Diagnosis of cerebral cysticercosis and evaluation of disease activity was based on CT scan findings. Specific IgG antibodies were found in the serum in 83.3% of patients with active disease and 10% of those with inactive disease. Cerebrospinal fluid tests evidenced specific antibodies in all patients with active disease and none of the patients with inactive disease. The specific CSF antibodies were IgG (94.4%), IgM (66.6%) or IgA (66.6%). Antibody titers were significantly higher in patients with an intraventricular vesicle or cyst.
Collapse
Affiliation(s)
- A Michault
- Service de Bactériologie-Parasitologie, Hôpital de Saint-Pierre de la Réunion, Centre Hospitalier Général de Saint-Pierre-Le-Tampon
| | | | | | | | | | | |
Collapse
|
25
|
Polydor JP, Mignard C, Dandelot JB. [The fear of suffering in patients with congenital insensitivity to pain]. Presse Med 1985; 14:2063-4. [PMID: 2417220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
|